[go: up one dir, main page]

FI20030393A7 - Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi - Google Patents

Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi Download PDF

Info

Publication number
FI20030393A7
FI20030393A7 FI20030393A FI20030393A FI20030393A7 FI 20030393 A7 FI20030393 A7 FI 20030393A7 FI 20030393 A FI20030393 A FI 20030393A FI 20030393 A FI20030393 A FI 20030393A FI 20030393 A7 FI20030393 A7 FI 20030393A7
Authority
FI
Finland
Prior art keywords
breast cancer
progression
17hsd
predict
treat
Prior art date
Application number
FI20030393A
Other languages
English (en)
Swedish (sv)
Other versions
FI20030393A0 (fi
FI20030393L (fi
Inventor
Pirkko Vihko
Veli Isomaa
Original Assignee
Molekyyliendokrinologian Tutkimusyksikkoe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molekyyliendokrinologian Tutkimusyksikkoe filed Critical Molekyyliendokrinologian Tutkimusyksikkoe
Priority to FI20030393A priority Critical patent/FI20030393A7/fi
Publication of FI20030393A0 publication Critical patent/FI20030393A0/fi
Priority to EP04720024A priority patent/EP1603571A2/en
Priority to PCT/FI2004/000145 priority patent/WO2004080271A2/en
Publication of FI20030393L publication Critical patent/FI20030393L/fi
Publication of FI20030393A7 publication Critical patent/FI20030393A7/fi
Priority to US11/225,095 priority patent/US20060057628A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Tämä keksintö käsittelee menetelmää naisen rintasyövän etenemisen prognostisoimiseen, joka menetelmä käsittää tyypin l 17beta-hydroksisteroididehydrogenaasienstyymin (17HSD) tason detektoimisen tai määrittämisen rintasyöpäkasvainkudoksesta, jossa mainitun tyypin l 17HSD-entsyymin läsnäolo on osoituksena vakavasta rintasyövän etenemisestä. Lisäksi keksintö käsittelee myös tyypin l 17HSD-entsyymin inhibiittorin käyttöä lääkkeenä rintasyövän estämisessä tai hoitamisessa. Tämä keksintö käsittelee myös 17HSD:n inhibiittorin käyttöä käyttökelpoisen farmaseuttisesti hyväksyttävän tuotteen valmistamisessa.
FI20030393A 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi FI20030393A7 (fi)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FI20030393A FI20030393A7 (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
EP04720024A EP1603571A2 (en) 2003-03-14 2004-03-12 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
PCT/FI2004/000145 WO2004080271A2 (en) 2003-03-14 2004-03-12 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
US11/225,095 US20060057628A1 (en) 2003-03-14 2005-09-14 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20030393A FI20030393A7 (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi

Publications (3)

Publication Number Publication Date
FI20030393A0 FI20030393A0 (fi) 2003-03-14
FI20030393L FI20030393L (fi) 2004-09-15
FI20030393A7 true FI20030393A7 (fi) 2004-09-15

Family

ID=8565817

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20030393A FI20030393A7 (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi

Country Status (4)

Country Link
US (1) US20060057628A1 (fi)
EP (1) EP1603571A2 (fi)
FI (1) FI20030393A7 (fi)
WO (1) WO2004080271A2 (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US8088758B2 (en) 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
RU2409581C2 (ru) * 2004-12-13 2011-01-20 Зольвай Фармасьютиклз Гмбх НОВЫЕ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ТИОФЕНПИРИМИДИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ
BRPI0419229A (pt) * 2004-12-13 2007-12-18 Solvay Pharm Gmbh derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
CN101884706B (zh) * 2010-07-01 2014-05-28 广州市花城制药厂 一种祛痰止咳颗粒的检测方法

Also Published As

Publication number Publication date
WO2004080271A2 (en) 2004-09-23
FI20030393A0 (fi) 2003-03-14
US20060057628A1 (en) 2006-03-16
WO2004080271A3 (en) 2004-11-04
EP1603571A2 (en) 2005-12-14
FI20030393L (fi) 2004-09-15

Similar Documents

Publication Publication Date Title
WO2004010937A3 (en) Method of treating cancer
MX2020004438A (es) El uso de inhibidores de la tirosina quinasa de bruton (btk).
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
SI1631295T1 (sl) Uporaba kondenziranih heterocikličnih spojin kotSCCE inhibitorjev za zdravljenje kožnih bolezni
HUP0302332A2 (hu) Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
NO20034549D0 (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
CY1110322T1 (el) Αναστολεις της her3 δραστικοτητας
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP2575884A4 (en) APPLICATIONS AND COMPOSITIONS FOR THE TREATMENT OF ACNE INVERSA
MX2010006854A (es) Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
FI20030393A7 (fi) Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
DE602005013085D1 (de) Proteinkinaseinhibitoren
MX2014000204A (es) Metodo de administracion y tratamiento.
WO2006057997A3 (en) Plasmin-inhibitory therapies
MX2021006210A (es) Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica.
DK2041181T3 (da) Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
WO2002074756A3 (de) Urokinase-inhibitoren
WO2009114817A3 (en) Pttg1 as a biomarker for cancer treatment
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии

Legal Events

Date Code Title Description
FD Application lapsed